Clinical trials: Bladder
Neurogenic Detrusor Overactivity, Overactive Bladder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
- Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
- Trial name
- NCT02211846
- Testing
- Mirabegron
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
Idiopathic Overactive Bladder, Bladder Training
Tibial Nerve and Extracorporeal Magnetic Stimulation for Overactive Bladder
Overactive bladder (OAB) syndrome is urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection.
- Conditions
- Idiopathic Overactive Bladder, Bladder Training, Transcutaneous Tibial Nerve Stimulation, Magnetic Stimulation
- Trial name
- NCT05387824
- Testing
- Magnetic stimulation -Armchair type MS • NovaMag NT-60, Electrical Stimulation- TTNS, Bladder Training
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pamukkale University
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
The study aims to establish the safety, tolerability, pharmacokinetics (PK), relevant biomarkers, pharmacodynamics (PD) and preliminary anti-tumor activity of the intravesical administration of eciskafusp alfa in combination with…
- Trial name
- NCT06816017
- Testing
- Eciskafusp Alfa, BCG Medac Strain
- Where
- 9 sites in Australia, Italy and 4 more
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma Bladder
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
Bladder cancer (BC) is the 6th most common tumor in Europe, with over 540,000 new cases globally each year. While 75% of cases are non-muscle-invasive and treated bladder-preservingly, muscle-invasive, non-metastatic BC requires…
- Trial name
- PRACTICE (NCT06806059)
- Testing
- Physical Activity
- Where
- Germany
- Volunteers
- 146 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Lower Urinary Tract Symptoms (LUTS)
Portuguese Mobile App Version of the ICIQ Bladder Diary for Adults With Urinary Symptoms: Development and Feasibility Study
The goal of this clinical trial is to evaluate a mobile app version of the International Consultation on Incontinence Questionnaire Bladder Diary (ICIQ-Bladder Diary) in Portuguese adults with urinary symptoms.
- Trial name
- NCT07602413
- Volunteers
- 40 people
- Sponsor
- Unidade Local de Saúde São João, Oporto
Interstitial Cystitis
Intravesical Liposomes for Ulcerative Cystitis
The objective is to instill liposomes reconstituted with sterile water into the bladder as a compassionate use treatment in one patient with ulcerative interstitial cystitis (IC).
- Trial name
- NCT01083979
- Testing
- Liposomes
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kenneth Peters, MD
Invasive Bladder Cancer, Bladder Cancer
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
The standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder.
- Trial name
- NCT02030574
- Testing
- Gemcitabine and fractionated cisplatin (combination treatment)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Overactive Bladder, Urinary Incontinence
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
- Conditions
- Overactive Bladder, Urinary Incontinence, Quality of Life
- Trial name
- MATRIX (NCT00224146)
- Testing
- oxybutynin transdermal delivery system (Oxytrol(r))
- Where
- 10 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Watson Pharmaceuticals
Urinary Bladder, Neurogenic, Neuropathic Bladder
Detrusor Contraction During the Ice-water-test
In this randomized, double-blind clinical trial including patients with a neurogenic lower urinary tract dysfunction undergoing urodynamic investigation at the Spinal Cord Injury Center, Balgrist University Hospital, Zürich, we…
- Trial name
- NCT01773213
- Testing
- Ice-water-test
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Balgrist University Hospital
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder Neoplasms
CIK in Treating Patients With Bladder Cancer
Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from…
- Trial name
- NCT02489890
- Testing
- Cytokine-induced Killer Cells
- Volunteers
- 1,500 people
- Sponsor
- The First People's Hospital of Changzhou
Overactive Bladder Syndrome, Urinary Urge Incontinence
Cycling Study With the Axonics System
A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
- Trial name
- NCT05543382
- Testing
- Axonics System
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Axonics, Inc.
Urinary Incontinence
Urge Incontinence Bladder Overactivity Study
Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency.
- Trial name
- NCT00475696
- Testing
- Duloxetine
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
- Trial name
- NCT00703703
- Testing
- Darifenacin, Tolterodine
- Where
- 21 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novartis
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Bladder Cancer, Bladder
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630
he primary objective is to characterize the safety profile of UGN-201 in patients with urothelial carcinoma undergoing radical cystectomy.
- Trial name
- NCT05055050
- Testing
- UGN-201
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Tract Infections, Prostatitis
Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study
In this protocol, investigators are examining the ability for a novel multiplex PCR assay with mixed floral antibiotic resistance profiling is safe and increases effective treatment for urinary tract infections in a urology…
- Conditions
- Urinary Tract Infections, Prostatitis, Interstitial Cystitis
- Trial name
- RapIDMixAR (NCT03931538)
- Testing
- Guidance 4.0 PCR test, Urine Culture
- Where
- United States
- Volunteers
- 2,511 people
- Sponsor
- Pathnostics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Prostate Cancer
Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion
Prostate cancer is the most common male cancer in global, which accounts for 19% of the total and poses great hazards to male health.
- Trial name
- CRADT (NCT03482089)
- Testing
- Cystoprostatectomy, external beam radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tongji Hospital